时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
In addition, it is uncertain whether any short-term symptomatic association is accompanied by measurable changes in systemic bone-turnover or inflammatory markers, and there is insufficient evidence to infer a local osteogenic mechanism from peripheral biomarkers.；The primary objective of this retrospective cohort study was therefore to compare 12-week fracture-site pain change between standard anti-osteoporosis treatment alone and standard treatment plus Xiaotong plaster.
方法
Systemic glucocorticoids remain an important component of MG treatment when rapid disease control is required or when steroid-sparing therapy is insufficient, delayed, contraindicated, or unavailable (2).Bone health is clinically important in elderly patients with MG.；Population-based evidence has shown an increased risk of osteoporosis in MG, particularly among corticosteroid-treated patients (3).；Fracture-risk estimates in MG have not been uniform across cohorts, indicating that glucocorticoid exposure, disease severity, reduced mobility, fall risk, vitamin D status, concomitant medications, and background osteoporosis care may contribute jointly to skeletal vulnerability (4, 5).
核心结论
Taken together, the evidence supports a short-term symptomatic association more strongly than immune modulation, structural skeletal benefit, or a specific osteogenic mechanism.The study population represents a clinically narrow but important subgroup.；They are compatible with a short-term difference in systemic remodeling, whereas the absence of a significant 12-month BMD difference argues against claiming a demonstrated structural skeletal effect.Osteoimmunology provides a useful framework for interpreting why inflammatory and skeletal responses may diverge.；These results should remain hypothesis-generating.
局限
However, pathway markers measured in peripheral blood or archived peripheral blood mononuclear cells cannot substitute for local fracture-site tissue measurements.；In particular, the post-weighting SMDs of 0.128 for teriparatide use and 0.112 for vertebral compression fracture distribution were treated as residual imbalance rather than as evidence that complete exchangeability had been achieved.The 12-week pain result should be interpreted separately from long-term skeletal outcomes.；However, a fracture-specific minimal clinically important difference was not prespecified for this heterogeneous fracture cohort; therefore, statistical significance should not be equated automatically with a large patient-perceived benefit.
对本项目的价值
中等价值：属「衰弱 / 肌少症功能结局」方向；肌肉骨骼 / 衰弱 / 肌少症栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.6/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 79,149 字符，题名指纹 1.0，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：老年重症肌无力合并糖皮质激素相关骨质疏松性脆性骨折患者外敷中药膏药辅助治疗的临床与骨转换结局：回顾性队列研究兼外周血 BMP-2/Smad/Runx2 探索性分析
- 英文标题：Clinical and bone-turnover outcomes associated with topical herbal plaster adjunctive therapy in older patients with myasthenia gravis and glucocorticoid-associated osteoporotic fragility fracture: a retrospective cohort study with exploratory peripheral-blood BMP-2/Smad/Runx2 analysis.
- 期刊与标识：Frontiers in immunology · PMID 42973645 · DOI 10.3389/fimmu.2026.1929809 · PMC PMC13724354